Insight velocity
Turn days of work into hours with reliable AI-driven analysis.














































Purpose-built for teams who need real insights—so you can focus on decisions, not research.
Strategic decisions deserve more than gut checks and stale decks. Maven Bio gives your team evidence-backed insights—and a living view of the market that doesn't go stale the moment it's built.







Speed is table stakes. Maven Bio gives your team the primary-source depth to deliver work that wins engagements—and keeps them.





IC questions deserve real answers. Maven Bio surfaces primary source analysis so your team builds theses that hold up under pressure.







Turn days of work into hours with reliable AI-driven analysis.
Execute large-scale screens once too slow or impractical to run.
Operationalize your frameworks so they're applied consistently by everyone.
Every insight tied directly to primary sources and reasoning for defensible decisions.

Powered by the most expansive collection of curated life sciences data.





A structured review of U.S. pharma manufacturing and R&D site investments announced in 2025, highlighting where capital was deployed, which companies announced site level expansions or new builds, and how these moves reinforce long term U.S. supply strategies.

Immunology remains the second-largest revenue category in global pharma, with multiple franchises now operating at a scale comparable to Humira at its peak. This report reviews the top-selling immunology drugs in Q3 2025, highlighting how indication expansion, portfolio transitions, and lifecycle management are reshaping competitive dynamics.

An analysis of disease-modifying therapies in type 1 diabetes, covering approved agents and late-stage pipeline programs across immunotherapy, cell therapy, and gene-based approaches reshaping treatment beyond insulin.